DATE: January 3, 2019 CIRCULOGENE Expands Molecular Diagnostics Testing Footprint To Asia-Pacific Region Strategic partnership broadens cancer-targeted molecular diagnostics and immunotherapy testing to rapidly growing Asia-Pacific market. BIRMINGHAM, Ala.– CIRCULOGENE, advancing precision medicine through molecular genetics [...]
FOR IMMEDIATE RELEASE DATE: December 20, 2018 CIRCULOGENE to Launch Comprehensive, 20-Fusion NTRK Biomarker Testing in Early 2019 Proprietary, cfRNA-enriched, real-time PCR testing rapidly identifies all patients with NTRK fusion-positive cancers potentially eligible for new TRK [...]
CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing Enables paired somatic-germline testing, broadens targeted treatment population for breast, ovarian, pancreatic and prostate cancers BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through molecular genetics testing, has [...]
CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients Independent UAB study demonstrates potential value of company’s molecular testing in noninvasive, serial tracking of genomic changes in treatment-resistant ovarian cancer BIRMINGHAM, Ala.– [...]
REQUEST FOR APPLICATIONS CIRCULOGENE – RESEARCH SAMPLE PROFILING PILOT AWARD PROGRAM Applications due: 5pm EST on August 1, 2018 Award announcements: anticipated by September 15, 2018 Pilot Award Details: Made possible by CIRCULOGENE, this pilot [...]
Advanced molecular genetics testing delivers lung cancer treatment decision with 5-day international turnaround. An Israeli oncologist referred his 63-year-old female lung cancer patient to the personalized cancer testing expertise of CIRCULOGENE looking for a faster treatment [...]
Single-tube liquid biopsy overcomes tissue biopsy failure to give oncologist personalized treatment decision guidance in matter of days. A southeastern oncologist treating a 66-year-old male with lung cancer was unable to obtain testing results due [...]
CIRCULOGENE testing rapidly matches young patient with targeted therapy for rare non-small-cell lung cancer genetic variation. An oncologist referred a blood sample on his 44-year-old female non-small cell lung cancer (NSCLC) patient to CIRCULOGENE for [...]
Publication: ACTA Scientific Cancer Biology Volume 2 Issue 1 January 2018 Abstract Quantity and quality of circulating cell-free DNA (cfDNA) from plasma is highly variable, with frequent contamination of larger, genomic DNA as a consequence [...]
CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory Company expands single-blood-tube, cancer-targeted therapy and immunotherapy testing to parts of Europe, Africa, the Middle East and Commonwealth of Independent States (CIS) [...]